Advanced search
Publication Cover
Current Medical Research and Opinion Volume 21, 2005 - Issue 7
Submit an article Journal homepage
66
Views
25
CrossRef citations to date
0
Altmetric
Original Article

Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease

Bonnie B. Dean Cerner Health Insights, Beverly Hills, CA, USA
,
Michelle Dylan Cerner Health Insights, Beverly Hills, CA, USA
,
Anacleto Gano Jr Cerner Health Insights, Beverly Hills, CA, USACorrespondence[email protected]
,
Kevin Knight Cerner Health Insights, Beverly Hills, CA, USA
,
Joshua J. Ofman Cerner Health Insights, Beverly Hills, CA, USA; Cedars–Sinai Departments of Medicine and Health Services Research, Los Angeles, CA, USA
&
Barton S. Levine VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
Pages 981-987 | Accepted 21 Apr 2005, Published online: 23 May 2005

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Francis Vekeman, Nadege-Desiree Yameogo, Patrick Lefebvre, Robert A. Bailey, R. Scott McKenzie & Catherine Tak Piech. (2010) Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients. Journal of Medical Economics 13:4, pages 673-680.
Read now
Viera Kupčová, Jan Šperl, Anne Pannier, Paul Jordan, Frank C. Dougherty & Bruno Reigner. (2008) The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A.. Current Medical Research and Opinion 24:7, pages 1943-1950.
Read now
Jeffrey Hoggard, Thomas Crouch, Stephen McMurray, Michael Levine, Radha Prathikanti, Debra Scarlata & Paul Audhya. (2006) Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Current Medical Research and Opinion 22:10, pages 2023-2030.
Read now

Articles from other publishers (22)

Sandra Ribeiro, Patrícia Garrido, João Fernandes, Helena Vala, Petronila Rocha-Pereira, Elísio Costa, Luís Belo, Flávio Reis & Alice Santos-Silva. (2016) Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose. Clinical and Experimental Pharmacology and Physiology 43:3, pages 343-354.
Crossref
Jacques Rottembourg, Patrick Tilleul, Gilbert Deray, Antoine Lafuma, Lorraine Zakin, Lamine Mahi & Jorge Wernli. (2014) Cost of managing anemia in end-stage renal disease: the experience of five French dialysis centers. The European Journal of Health Economics 16:4, pages 357-364.
Crossref
Emad E. Ghobrial, Khaled M. Salama, Maha F. Shiba & Naglaa H. El Shafae. (2013) The effect of anemia management on chronic renal failure progression. Egyptian Pediatric Association Gazette 61:1, pages 37-41.
Crossref
Judit Gordon & Jeffrey B. Kopp. (2011) Off the Beaten Renin–Angiotensin–Aldosterone System Pathway: New Perspectives on Antiproteinuric Therapy. Advances in Chronic Kidney Disease 18:4, pages 300-311.
Crossref
R. Ravasio, M. D’Orsi, G. F. Zuccotti, A. Girlanda, D. Cantù, C. Buffa & M. De Petris. (2013) Analisi dei consumi e dei costi degli agenti stimolanti l’eritropoiesi nel trattamento dell’anemia nei pazienti con insufficienza renale cronica: l’esperienza della ASL della provincia di AlessandriaEvaluation of dosages and costs associated with the use of erythropoietin receptor agonists in the treatment of anemia in patients with chronic kidney disease: the Local Health Unit of Alessandria experience. PharmacoEconomics Italian Research Articles 12:3, pages 167-174.
Crossref
Anil K. Agarwal & Ajay K. Singh. (2010) Therapy with Erythropoiesis-Stimulating Agents and Renal and Nonrenal Outcomes. Heart Failure Clinics 6:3, pages 323-332.
Crossref
B. B. Newsome, S. J. Onufrak, D. G. Warnock & W. M. McClellan. (2009) Exploration of anaemia as a progression factor in African Americans with cardiovascular disease. Nephrology Dialysis Transplantation 24:11, pages 3404-3411.
Crossref
Andrea Luk & Juliana C.N. Chan. (2008) Diabetic nephropathy—What are the unmet needs?. Diabetes Research and Clinical Practice 82, pages S15-S20.
Crossref
R. Ravasio, C. Cerra & P. Fratino. (2013) Analisi dei consumi e dei costi degli agenti stimolanti l’eritropoiesi nel trattamento dell’anemia nei pazienti con insufficienza renale cronicaEvaluation of dosages and costs associated with the use of erythropoietin receptor agonists in the treatment of anemia in patients with chronic kidney disease. PharmacoEconomics Italian Research Articles 10:3, pages 161-169.
Crossref
S. D. Roger. (2008) Extended administration of erythropoiesis-stimulating agents for optimising the management of renal anaemia: what is the evidence?. International Journal of Clinical Practice 62:9, pages 1413-1422.
Crossref
Sarah Tomasello. (2008) Anemia of Chronic Kidney Disease. Journal of Pharmacy Practice 21:3, pages 181-195.
Crossref
Samina Khan & Chester A. Amedia. (2008) Economic burden of chronic kidney disease. Journal of Evaluation in Clinical Practice 14:3, pages 422-434.
Crossref
Érick MoyneurBrahim K. BookhartSamir H. ModyAndrée-Anne FournierDavid MallettMei Sheng Duh. (2008) The Economic Impact of Pre-Dialysis Epoetin Alfa on Health Care and Work Loss Costs in Chronic Kidney Disease: An Employer's Perspective. Disease Management 11:1, pages 49-58.
Crossref
Bruce Spinowitz, Daniel W. Coyne, Charmaine E. Lok, Mario Fraticelli, Maher Azer, Sanjay Dalal, Giuseppe Villa, Steven Rosansky, Helena Adamis & Ulrich Beyer. (2008) C.E.R.A. Maintains Stable Control of Hemoglobin in Patients with Chronic Kidney Disease on Dialysis when Administered Once Every Two Weeks. American Journal of Nephrology 28:2, pages 280-289.
Crossref
M. Nangaku & D. Fliser. (2007) Erythropoiesis-stimulating agents: Past and future. Kidney International 72, pages S1-S3.
Crossref
N. Eto, T. Wada, R. Inagi, H. Takano, A. Shimizu, H. Kato, H. Kurihara, H. Kawachi, S.J. Shankland, T. Fujita & M. Nangaku. (2007) Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney International 72:4, pages 455-463.
Crossref
William McClellan, Rebecca Speckman, Leslie McClure, Virginia Howard, Ruth C. Campbell, Mary Cushman, Paul Audhya, George Howard & David G. Warnock. (2007) Prevalence and Characteristics of a Family History of End-Stage Renal Disease among Adults in the United States Population: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Renal Cohort Study. Journal of the American Society of Nephrology 18:4, pages 1344-1352.
Crossref
Patrick LefebvreMei Sheng DuhSamir H. ModyBrahim BookhartCatherine Tak Piech. (2007) The Economic Impact of Epoetin Alfa Therapy on Delaying Time to Dialysis in Elderly Patients with Chronic Kidney Disease. Disease Management 10:1, pages 37-45.
Crossref
PETER G KERR. (2006) Renal anaemia: Recent developments, innovative approaches and future directions for improved management (Review Article). Nephrology 11:6, pages 542-548.
Crossref
A. K. AGARWAL, M. R. SILVER, J. E. REED, R. K. DHINGRA, W. LIU, N. VARMA & C. STEHMAN-BREEN. (2006) An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. Journal of Internal Medicine 260:6, pages 577-585.
Crossref
X. L. Yang, W. Y. So, A. P. S. Kong, P. Clarke, C. S. Ho, C. W. K. Lam, M. H. L. Ng, R. R. Lyu, D. D. Yin, C. C. Chow, C. S. Cockram, P. C. Y. Tong & J. C. N. Chan. (2006) End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry. Diabetologia 49:10, pages 2299-2308.
Crossref
Claudine Jurkovitz, Jerome Abramson & William M McClellan. (2006) Anemia and cardiovascular and kidney disease. Current Opinion in Nephrology and Hypertension 15:2, pages 117-122.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.